Asymmetric dimethylarginine—comparison of HPLC and ELISA methods

Siroka, Romana; Trefil, Ladislav; Rajdl, Daniel; Ráček, Jaroslav; Cibulka, Roman

doi:10.1016/j.jchromb.2006.12.009

Cited by 19 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, the results in Kielstein's and our study are proportionate (1/3 rate of ADMA removal and 1/3 plasma ADMA levels in our study), and differences in absolute values of plasma and dialysate ADMA are most likely due to a different method of ADMA assessment (HPLC and ELISA, respectively). The ELISA method was shown to correlate closely with HPLC in our previous study (19). In the present study, the 1-week ADMA removal rate into dialysate in the HD/HDF group was higher by a factor of 3.5 compared to the PD group.…”

Section: Adma and Renal Replacement Therapy 423supporting

confidence: 78%

Asymmetric Dimethylarginine in Hemodialysis, Hemodiafiltration, and Peritoneal Dialysis

et al. 2010

View full text Add to dashboard Cite

Asymmetric dimethylarginine (ADMA) is a mediator of endothelial dysfunction. Production and elimination of ADMA may be affected by the type of renal replacement therapy used and oxidative stress. Plasma ADMA, advanced glycation end products (AGE), and homocysteine were assessed in 59 subjects: 20 hemodialysis (HD) patients, 19 patients undergoing peritoneal dialysis (PD), and 20 controls. Results were compared between the groups. The effect of 8 weeks of HD and high-volume predilution hemodiafiltration (HDF) was compared in a randomized study. HD patients showed higher ADMA (1.20 [0.90-1.39 micromol/L]) compared to controls (0.89 [0.77-0.98], P < 0.01), while ADMA in PD did not differ from controls (0.96 [0.88-1.28]). AGE and homocysteine were highest in HD, lower in PD (P < 0.01 vs. HD), and lowest in controls (P < 0.001 vs. HD and PD). PD patients had higher residual renal function than HD (P < 0.01). The decrease in ADMA at the end of HD (from 1.25 [0.97-1.33] to 0.66 [0.57-0.73], P < 0.001) was comparable to that of HDF. Switching from HD to HDF led to a decrease in predialysis homocysteine level in 8 weeks (P < 0.05), while ADMA and AGE did not change. Increased ADMA levels in patients undergoing HD, as compared to PD, may be caused by higher oxidative stress and lower residual renal function in HD. Other factors, such as diabetes and statin therapy, may also be at play. The decrease in ADMA at the end of HD and HDF is comparable. Switching from HD to HDF decreases in 8 weeks the predialysis levels of homocysteine without affecting ADMA.

show abstract

Section: Adma and Renal Replacement Therapy 423supporting

confidence: 78%

Asymmetric Dimethylarginine in Hemodialysis, Hemodiafiltration, and Peritoneal Dialysis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Previous comparative studies found ELISA to overestimate plasma ADMA concentrations compared to HPLC [19,33,34]. …”

Section: Discussionmentioning

confidence: 99%

“…ELISA is an easy-to-use, fast method with the disadvantage of less sensitivity. Regarding the comparability of these methods, in case of the analysis of the same samples Schulze et al found nearly identical ADMA levels measured by ELISA and HPLC, while in another study Shiroka et al found ELISA to overestimate ADMA values compared to HPLC[18, 19]. Several studies aimed to determine the reference range of plasma ADMA, regrettably only few of them investigated completely healthy individuals (Table 1).…”

Section: Introductionmentioning

confidence: 99%

The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

BackgroundAsymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase, marker and mediator of endothelial dysfunction. Several studies have demonstrated its value in cardiovascular risk stratification and all-cause mortality prediction. The aim was to determine the reference range of plasma ADMA in healthy adults.Methods and resultsTaking into account the most widely used ADMA measurement methods, only studies using either high performance liquid chromatography (HPLC) -with fluorescence or mass spectrometric detection-, or enzyme-linked immunosorbent assay (ELISA) to quantify plasma ADMA concentrations were enrolled. 66 studies were included in the quantitative analysis (24 using ELISA and 42 using HPLC) reporting a total number of 5528 non-diabetic, non-hypertensive, non-obese adults without any medication (3178 men and 2350 women, 41.6 ± 16.9 years old). The reference range of ADMA (in μmol/l with 95% confidence interval in parenthesis) was 0.34 (0.29–0.38)– 1.10 (0.85–1.35) with a mean of 0.71 (0.57–0.85) (n = 4093) measured by HPLC and 0.25 (0.18–0.31)– 0.92 (0.76–1.09) with a mean of 0.57 (0.48–0.66) (n = 1435) by ELISA.ConclusionsNumerous publications suggested that asymmetric dimethylarginine is not only an outstanding tool of disease outcome prediction but also a new potential therapeutic target substance; the reference range provided by this meta-analysis can become of great importance and aid to further investigations. However, developing a standard measurement method would be beneficial to facilitate the clinical usage of ADMA.

show abstract

“…However, results obtained by ELISA are significantly higher than those from robust chromatographic methods, as has been shown in comparisons with HPLC 129,130 and LC-MS. 131 On average, ELISA yields concentrations approximately twice as high as those from chromatographic methods, suggesting matrix effects or calibration problems. 129,131 One group performing a comparison, however, found no between 10th and 90th centiles ................................................................................................................................................ Blackwell. Biochemistry, measurement and current clinical significance of ADMA correlation between the methods.…”

Section: Measurement Of Admamentioning

confidence: 91%

The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine

Blackwell

2009

Ann Clin Biochem

View full text Add to dashboard Cite

Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and an important cause of endothelial dysfunction. Its increased plasma concentration is associated with a variety of traditional cardiovascular risk factors, and may mediate their effects on the vascular endothelium. ADMA is also an independent predictor of cardiovascular events and mortality, and predicts outcomes in critically ill patients in the intensive care unit. This work has provided insights into the role of ADMA as an endogenous regulator of nitric oxide synthesis. At present there is no specific therapy to modify ADMA concentration, but increasing interest and work on protein arginine methyltransferases and dimethylarginine dimethylaminohydrolase, which synthesize and metabolize ADMA, respectively, might provide novel therapeutic targets.

show abstract

Asymmetric dimethylarginine—comparison of HPLC and ELISA methods

Cited by 19 publications

References 11 publications

Asymmetric Dimethylarginine in Hemodialysis, Hemodiafiltration, and Peritoneal Dialysis

Asymmetric Dimethylarginine in Hemodialysis, Hemodiafiltration, and Peritoneal Dialysis

The issue of plasma asymmetric dimethylarginine reference range – A systematic review and meta-analysis

The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine

Contact Info

Product

Resources

About